These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 6408427)

  • 21. Conduct of drug trials in poor countries must improve.
    Richards T
    BMJ; 2005 Jun; 330(7506):1466. PubMed ID: 15976407
    [No Abstract]   [Full Text] [Related]  

  • 22. Institute of Medicine's new drug safety report: implications for Canada.
    Cassels A
    CMAJ; 2006 Dec; 175(12):1515-6. PubMed ID: 17146086
    [No Abstract]   [Full Text] [Related]  

  • 23. WHO and industry combine to form ethics body.
    Dickson D
    Nat Med; 2002 Jul; 8(7):645. PubMed ID: 12091885
    [No Abstract]   [Full Text] [Related]  

  • 24. Post-marketing drug surveillance: an idea whose time has come.
    Strom BL
    Drug Ther; 1982; ():155-63. PubMed ID: 7105991
    [No Abstract]   [Full Text] [Related]  

  • 25. [New guidelines of the European Union. Motivation for drug testing in pediatrics].
    Appel K
    Dtsch Med Wochenschr; 2001 May; 126(18):A403. PubMed ID: 11381643
    [No Abstract]   [Full Text] [Related]  

  • 26. Web alert. The chemistry of metabolic and toxicological processes.
    Cavalla D
    Curr Opin Drug Discov Devel; 2001 Jan; 4(1):25-6. PubMed ID: 11727319
    [No Abstract]   [Full Text] [Related]  

  • 27. Ethical issues of clinical trials in children: a European perspective.
    Sammons H
    Arch Dis Child; 2009 Jun; 94(6):474-7. PubMed ID: 19208673
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Priorities in the benefit-risk assessment of new drugs.
    Venning GR
    Adverse Drug React Acute Poisoning Rev; 1984; 3(2):113-21. PubMed ID: 6543414
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The adverse effects of drugs: the hidden part of the iceberg].
    Roca-Cusachs A; Rodicio JL
    Med Clin (Barc); 1999 Apr; 112(13):516-7. PubMed ID: 10353120
    [No Abstract]   [Full Text] [Related]  

  • 30. Publication is positively skewed.
    Bjorn G
    Nat Med; 2008 Nov; 14(11):1133. PubMed ID: 18989267
    [No Abstract]   [Full Text] [Related]  

  • 31. Register or perish. Looking to make the downside of therapies known.
    Krakovsky M
    Sci Am; 2004 Dec; 291(6):18, 20. PubMed ID: 15597973
    [No Abstract]   [Full Text] [Related]  

  • 32. An integrated, multidisciplinary approach for drug safety assessment.
    Li AP
    Drug Discov Today; 2004 Aug; 9(16):687-93. PubMed ID: 15341779
    [No Abstract]   [Full Text] [Related]  

  • 33. [Defining trials of medicinal products according to the revised Dutch Medical Research in Human Subjects Act (WMO)].
    Vos EJ; Huitema AD
    Ned Tijdschr Geneeskd; 2006 Sep; 150(38):2104-7. PubMed ID: 17036864
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adverse drug reactions--when is an adverse drug reaction not an adverse drug reaction?
    Leber P
    Psychopharmacol Bull; 1982 Apr; 18(2):6-9. PubMed ID: 7051080
    [No Abstract]   [Full Text] [Related]  

  • 35. An introductory note to CHMP guidelines: choice of the non-inferiority margin and data monitoring committees.
    Brown D; Volkers P; Day S
    Stat Med; 2006 May; 25(10):1623-7. PubMed ID: 16639776
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug safety--important to us all!
    Böttiger LE
    J Intern Med; 2001 Oct; 250(4):269-70. PubMed ID: 11576314
    [No Abstract]   [Full Text] [Related]  

  • 37. [Application of good clinical practices. An example of organization].
    Nys V; Terrier JL; Certain B; Costantini D
    Ann Pharm Fr; 1999 Nov; 57(6):468-75. PubMed ID: 10605153
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmaceutical use and outcomes in children.
    Mullins CD
    Clin Ther; 2009 Feb; 31(2):420. PubMed ID: 19302914
    [No Abstract]   [Full Text] [Related]  

  • 39. Placebo in clinical drug trials--a multidisciplinary review.
    Haegerstam G; Huitfeldt B; Nilsson BS; Sjövall J; Syvälahti E; Wahlén A
    Methods Find Exp Clin Pharmacol; 1982; 4(4):261-78. PubMed ID: 6750286
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sequential design approaches for bioequivalence studies with crossover designs.
    Potvin D; DiLiberti CE; Hauck WW; Parr AF; Schuirmann DJ; Smith RA
    Pharm Stat; 2008; 7(4):245-62. PubMed ID: 17710740
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.